Literature DB >> 17406756

Bcl-2 expression in rectal cancer.

Paulo C Contu1, Simone S Contu, Luis F Moreira.   

Abstract

BACKGROUND: [corrected] Proteins involved in apoptosis process seem to play an important role in colorectal carcinogenesis AIM: To determine the prevalence of bcl-2 protein immunohistochemical expression and its relation with clinical and histopathological variables of rectal adenocarcinoma. PATIENTS AND METHODS: One hundred and thirty-two patients operated at "Hospital de Clínicas de Porto Alegre", Porto Alegre, RS, Brazil, between 1988 and 1999 were studied through immunohistochemical reaction using a monoclonal antibody anti-bcl-2 on formalin-fixed, paraffin-embedded tissue samples
RESULTS: The prevalence of bcl-2 protein was 29.5%. There was a significant increased number of positive bcl-2 cases among women as compared to men. There was no significant association between bcl-2 and age, tumour site, histological grade, mucin production, depth of invasion, lymphatic involvement, distant metastasis or stage, despite a trend showing decreased immunoreactivity to bcl-2 among poorly and moderately differentiated tumours, as well as disseminated disease
CONCLUSIONS: Analysis of bcl-2 protein expression in tumour tissues, as well as other oncoproteins, may have a role in predict therapeutic response and prognosis of colorectal cancer. However, the potential use of bcl-2 protein assessment in the clinical set for management of rectal cancer remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17406756     DOI: 10.1590/s0004-28032006000400008

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  6 in total

1.  Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation.

Authors:  Benjamin D Zeitlin; Aaron C Spalding; Marcia S Campos; Naoki Ashimori; Zhihong Dong; Shaomeng Wang; Theodore S Lawrence; Jacques E Nör
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-01       Impact factor: 7.038

2.  RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Dongsheng Wang; Lydia Koenig; Sreenivas Nannapaneni; Zhengjia Chen; Zhibo Wang; Gabriel Sica; Xingming Deng; Zhuo Georgia Chen; Dong M Shin
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

Review 3.  Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.

Authors:  Benjamin D Zeitlin; Isaac J Zeitlin; Jacques E Nör
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

4.  Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation.

Authors:  Atilla Kurt; Fatih Yanar; Oktar Asoglu; Emre Balik; Vakur Olgac; Hasan Karanlik; Sevda Tanrikulu Kucuk; Evin Ademoglu; Gulcin Yegen; Dursun Bugra
Journal:  BMC Clin Pathol       Date:  2012-12-31

5.  Apoptotic and Necroptotic Mediators are Differentially Expressed in Mucinous and Non-Mucinous Colorectal Cancer.

Authors:  Emer O'Connell; Ian S Reynolds; Andreas U Lindner; Manuela Salvucci; Tony O'Grady; Orna Bacon; Sanghee Cho; Elizabeth McDonough; Daniel Longley; Fiona Ginty; Deborah A McNamara; John P Burke; Jochen H M Prehn
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

6.  Histopathological Evaluation and Analysis of Immunohistochemical Expression of Bcl-2 Oncoprotein in Colorectal Carcinoma.

Authors:  Shilpa T Patil; Clement Wilfred D; Prasanna Shetty B
Journal:  Iran J Pathol       Date:  2019-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.